Suppr超能文献

作为人蛋白激酶CK2抑制剂的茚并[1,2 - b]吲哚类药效团模型的开发及数据库挖掘

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining.

作者信息

Haidar Samer, Bouaziz Zouhair, Marminon Christelle, Laitinen Tuomo, Poso Antti, Le Borgne Marc, Jose Joachim

机构信息

Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, Corrensstr. 48, 48149 Münster, Germany.

Faculty of Pharmacy, Damascus University, Damascus, P.O. Box 9411, Syria.

出版信息

Pharmaceuticals (Basel). 2017 Jan 9;10(1):8. doi: 10.3390/ph10010008.

Abstract

Protein kinase CK2, initially designated as casein kinase 2, is an ubiquitously expressed serine/threonine kinase. This enzyme, implicated in many cellular processes, is highly expressed and active in many tumor cells. A large number of compounds has been developed as inhibitors comprising different backbones. Beside others, structures with an indeno[1,2-]indole scaffold turned out to be potent new leads. With the aim of developing new inhibitors of human protein kinase CK2, we report here on the generation of common feature pharmacophore model to further explain the binding requirements for human CK2 inhibitors. Nine common chemical features of indeno[1,2-]indole-type CK2 inhibitors were determined using MOE software (Chemical Computing Group, Montreal, Canada). This pharmacophore model was used for database mining with the aim to identify novel scaffolds for developing new potent and selective CK2 inhibitors. Using this strategy several structures were selected by searching inside the ZINC compound database. One of the selected compounds was bikaverin (6,11-dihydroxy-3,8-dimethoxy-1-methylbenzo[]xanthene-7,10,12-trione), a natural compound which is produced by several kinds of fungi. This compound was tested on human recombinant CK2 and turned out to be an active inhibitor with an IC value of 1.24 µM.

摘要

蛋白激酶CK2最初被命名为酪蛋白激酶2,是一种广泛表达的丝氨酸/苏氨酸激酶。这种酶参与许多细胞过程,在许多肿瘤细胞中高表达且具有活性。已经开发出大量包含不同骨架的化合物作为抑制剂。其中,具有茚并[1,2 -]吲哚支架的结构被证明是有效的新先导化合物。为了开发人类蛋白激酶CK2的新型抑制剂,我们在此报告生成通用特征药效团模型,以进一步解释人类CK2抑制剂的结合要求。使用MOE软件(加拿大蒙特利尔化学计算集团)确定了茚并[1,2 -]吲哚型CK2抑制剂的九个常见化学特征。该药效团模型用于数据库挖掘,目的是识别用于开发新型强效和选择性CK2抑制剂的新支架。使用这种策略,通过在ZINC化合物数据库中搜索选择了几种结构。所选化合物之一是比卡韦林(6,11 - 二羟基 - 3,8 - 二甲氧基 - 1 - 甲基苯并[]呫吨 - 7,10,12 - 三酮),一种由多种真菌产生的天然化合物。该化合物在人重组CK2上进行了测试,结果证明是一种活性抑制剂,IC值为1.24 μM。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd87/5374412/9487b560a537/pharmaceuticals-10-00008-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验